Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL

Share :
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 22 Feb 2022
Views: 1774
Dr Juliana Pereira & Dr Steven Horwitz

Dr Juliana Pereira (University of São Paulo, São Paulo, Brazil) and Dr Steven Horwitz (Memorial Sloan Kettering Cancer Service, Basking Ridge, USA) talk about the the Echelon-2 trial.

This was a 5-year exploratory subgroup analyses of a randomised, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) Vs CHOP in frontline treatment of patients with CD30-positive peripheral T-Cell Lymphoma.

They talk about the current PTCL treatment and treatment sequence.

Dr Pereira says that for CD30 detection, currently there’s no standard even in the same country. Some hospitals use IHC, some use FC.

Dr Horwitz talks about the interpretation method of CD30 staining I.e; qualitative method vs quantitative methods to report the percentage of CD30 positive cells. They discuss how this gap can be filled up.

They also talk about the background and results of the ECHELON-2 study and the clinical impact of the results form ECHELON-2 study.

This programme has been supported by an unrestricted educational grant from Takeda